Literature DB >> 23124573

Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis.

Ramin Shayan1, Rachael Inder, Tara Karnezis, Carol Caesar, Karri Paavonen, Mark W Ashton, G Bruce Mann, G Ian Taylor, Marc G Achen, Steven A Stacker.   

Abstract

Tumor metastasis to lymph nodes is a key indicator of patient survival, and is enhanced by the neo-lymphatics induced by tumor-secreted VEGF-C or VEGF-D, acting via VEGFR-3 signalling. These targets constitute important avenues for anti-metastatic treatment. Despite this new understanding, clinical observations linking metastasis with tumor depth or location suggest that lymphangiogenic growth factors are not the sole determinants of metastasis. Here we explored the influence of tumor proximity to lymphatics capable of responding to growth factors on nodal metastasis in a murine VEGF-D over-expression tumor model. We found that primary tumor location profoundly influenced VEGF-D-mediated lymph node metastasis: 89 % of tumors associated with the flank skin metastasised, in contrast with only 19 % of tumors located more deeply on the body wall (p < 0.01). Lymphatics in metastatic tumors arose from small lymphatics, and displayed distinct molecular and morphological profiles compared with those found in normal lymphatics. Smaller lymphatic subtypes were more abundant in skin (2.5-fold, p < 0.01) than in body wall, providing a richer source of lymphatics for VEGF-D(+) skin tumors, a phenomenon also confirmed in human samples. This study shows that the proximity of a VEGF-D(+) primary tumor to small lymphatics is an important determinant of metastasis. These observations may explain why tumor location relative to the lymphatic network is prognostically important for some human cancers.

Entities:  

Mesh:

Year:  2012        PMID: 23124573     DOI: 10.1007/s10585-012-9541-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  48 in total

1.  Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate.

Authors:  Giacomo Azzali
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.

Authors:  Tohru Hoshida; Naohide Isaka; Jeroen Hagendoorn; Emmanuelle di Tomaso; Yen-Lin Chen; Bronislaw Pytowski; Dai Fukumura; Timothy P Padera; Rakesh K Jain
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Vascular endothelial growth factor-C accelerates diabetic wound healing.

Authors:  Anne Saaristo; Tuomas Tammela; Anniina Farkkilā; Marika Kärkkäinen; Erkki Suominen; Seppo Yla-Herttuala; Kari Alitalo
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

4.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.

Authors:  Tara Karnezis; Ramin Shayan; Carol Caesar; Sally Roufail; Nicole C Harris; Kathryn Ardipradja; You Fang Zhang; Steven P Williams; Rae H Farnsworth; Ming G Chai; Thusitha W T Rupasinghe; Dedreia L Tull; Megan E Baldwin; Erica K Sloan; Stephen B Fox; Marc G Achen; Steven A Stacker
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

5.  Is risk of axillary lymph node metastasis associated with proximity of breast cancer to the skin?

Authors:  Joan E Cunningham; Adriana L Jurj; Leah Oman; Amy E Stonerock; Daniela K Nitcheva; Tommy E Cupples
Journal:  Breast Cancer Res Treat       Date:  2006-07-06       Impact factor: 4.872

6.  VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.

Authors:  W Debinski; B Slagle-Webb; M G Achen; S A Stacker; E Tulchinsky; G Y Gillespie; D M Gibo
Journal:  Mol Med       Date:  2001-09       Impact factor: 6.354

7.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

8.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

9.  Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma.

Authors:  James S Goydos; David H Gorski
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

Review 10.  Lymphatic endothelium: morphological, molecular and functional properties.

Authors:  Michael S Pepper; Mihaela Skobe
Journal:  J Cell Biol       Date:  2003-10-27       Impact factor: 10.539

View more
  10 in total

Review 1.  Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Authors:  Steven A Stacker; Steven P Williams; Tara Karnezis; Ramin Shayan; Stephen B Fox; Marc G Achen
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  Generation of homologous cell pairs using the oral lymphatic system.

Authors:  Yin-Fei Pu; Lin Wang; Huan-Huan Wu; Huan Bian; Ying-Ying Hong; Yi-Xiang Wang; Chuan-Bin Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

3.  Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.

Authors:  Roben G Gieling; Richard J Fitzmaurice; Brian A Telfer; Muhammad Babur; Kaye J Williams
Journal:  Clin Exp Metastasis       Date:  2015-06-26       Impact factor: 5.150

4.  Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.

Authors:  Masataka Matsumoto; Sally Roufail; Rachael Inder; Carol Caesar; Tara Karnezis; Ramin Shayan; Rae H Farnsworth; Teruhiko Sato; Marc G Achen; G Bruce Mann; Steven A Stacker
Journal:  Clin Exp Metastasis       Date:  2013-04-17       Impact factor: 5.150

5.  Establishment of risk prediction nomogram for ipsilateral axillary lymph node metastasis in T1 breast cancer.

Authors:  Yuanyuan Fu; Jingxin Jiang; Shuzheng Chen; Fuming Qiu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-02-25

Review 6.  The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.

Authors:  Shona A Hendry; Rae H Farnsworth; Benjamin Solomon; Marc G Achen; Steven A Stacker; Stephen B Fox
Journal:  Front Immunol       Date:  2016-12-20       Impact factor: 7.561

7.  Systematic high-content genome-wide RNAi screens of endothelial cell migration and morphology.

Authors:  Steven P Williams; Cathryn M Gould; Cameron J Nowell; Tara Karnezis; Marc G Achen; Kaylene J Simpson; Steven A Stacker
Journal:  Sci Data       Date:  2017-03-01       Impact factor: 6.444

8.  Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.

Authors:  Alexandra R Harris; Matthew J Perez; Jennifer M Munson
Journal:  BMC Cancer       Date:  2018-07-06       Impact factor: 4.430

9.  Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients.

Authors:  Yuanxin Zhang; Ji Li; Yuan Fan; Xiaomin Li; Juanjuan Qiu; Mou Zhu; Hongjiang Li
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

10.  Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma.

Authors:  Wei Ma; Kai Wang; Shaoqi Yang; Jianbo Wang; Bingxu Tan; Bing Bai; Nana Wang; Yibin Jia; Ming Jia; Yufeng Cheng
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.